Zhengguo Qiu, Xiaqing Zhang, Ni Jia, Xu Li, Rui Li, S. Gopinath, Mingna Jiao
{"title":"通过双分子探针阻抗传感器诊断阿尔茨海默病的沸石纳米材料修饰氧化电极表面","authors":"Zhengguo Qiu, Xiaqing Zhang, Ni Jia, Xu Li, Rui Li, S. Gopinath, Mingna Jiao","doi":"10.1515/tjb-2023-0079","DOIUrl":null,"url":null,"abstract":"Abstract Objectives Alzheimer’s disease (AD) is an irreversible and progressive neurogenerative disorder, which affects the learning part of brain. It mainly affects the aged population and becoming a global health issue, expecting to increase more in near future. Late diagnosis of AD worsens the situation and difficult to treat the patient. Various biosensing techniques with suitable biomarkers have been developed by researchers to diagnose the earlier stages of AD. Methods This research was focused to develop a highly sensitive zeolite-dual probe-modified impedance biosensor for identifying AD biomarker, Aβ Oligomer (AβO). The sensing surface was initially modified with zeolite through the chemical linker and then a dual probe of anti-AβO aptamer and anti-AβO antibody were attached to the surface of the zeolite. Results On these dual probe-modified surfaces, AβO was quantified to diagnose AD. Further, AβO spiked artificial CSF was identified by dual probes without any interference, indicating the selective identification of AβO. In addition, control experiments with non-immune, complementary, and control proteins failed to show the increment of responses, confirming the specific detection of AβO. Conclusions This zeolite-dual probe-modified biosensor helps to lower the limit of detection to 0.1 pM and diagnose AD at the earlier stages.","PeriodicalId":23344,"journal":{"name":"Turkish Journal of Biochemistry","volume":"60 13","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Zeolite nanomaterial-modified dielectrode oxide surface for diagnosing Alzheimer’s disease by dual molecular probed impedance sensor\",\"authors\":\"Zhengguo Qiu, Xiaqing Zhang, Ni Jia, Xu Li, Rui Li, S. Gopinath, Mingna Jiao\",\"doi\":\"10.1515/tjb-2023-0079\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Objectives Alzheimer’s disease (AD) is an irreversible and progressive neurogenerative disorder, which affects the learning part of brain. It mainly affects the aged population and becoming a global health issue, expecting to increase more in near future. Late diagnosis of AD worsens the situation and difficult to treat the patient. Various biosensing techniques with suitable biomarkers have been developed by researchers to diagnose the earlier stages of AD. Methods This research was focused to develop a highly sensitive zeolite-dual probe-modified impedance biosensor for identifying AD biomarker, Aβ Oligomer (AβO). The sensing surface was initially modified with zeolite through the chemical linker and then a dual probe of anti-AβO aptamer and anti-AβO antibody were attached to the surface of the zeolite. Results On these dual probe-modified surfaces, AβO was quantified to diagnose AD. Further, AβO spiked artificial CSF was identified by dual probes without any interference, indicating the selective identification of AβO. In addition, control experiments with non-immune, complementary, and control proteins failed to show the increment of responses, confirming the specific detection of AβO. Conclusions This zeolite-dual probe-modified biosensor helps to lower the limit of detection to 0.1 pM and diagnose AD at the earlier stages.\",\"PeriodicalId\":23344,\"journal\":{\"name\":\"Turkish Journal of Biochemistry\",\"volume\":\"60 13\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Turkish Journal of Biochemistry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/tjb-2023-0079\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Biochemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/tjb-2023-0079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Zeolite nanomaterial-modified dielectrode oxide surface for diagnosing Alzheimer’s disease by dual molecular probed impedance sensor
Abstract Objectives Alzheimer’s disease (AD) is an irreversible and progressive neurogenerative disorder, which affects the learning part of brain. It mainly affects the aged population and becoming a global health issue, expecting to increase more in near future. Late diagnosis of AD worsens the situation and difficult to treat the patient. Various biosensing techniques with suitable biomarkers have been developed by researchers to diagnose the earlier stages of AD. Methods This research was focused to develop a highly sensitive zeolite-dual probe-modified impedance biosensor for identifying AD biomarker, Aβ Oligomer (AβO). The sensing surface was initially modified with zeolite through the chemical linker and then a dual probe of anti-AβO aptamer and anti-AβO antibody were attached to the surface of the zeolite. Results On these dual probe-modified surfaces, AβO was quantified to diagnose AD. Further, AβO spiked artificial CSF was identified by dual probes without any interference, indicating the selective identification of AβO. In addition, control experiments with non-immune, complementary, and control proteins failed to show the increment of responses, confirming the specific detection of AβO. Conclusions This zeolite-dual probe-modified biosensor helps to lower the limit of detection to 0.1 pM and diagnose AD at the earlier stages.